HKEX:1276) fell HK$2.70 to HK$71.95 on Tuesday after announcing data from a Phase III trial of HRS9531 was positive but failed to differentiate from GLP-1/GIP agonist Zepbound tirzepatide marketed by Eli Lilly and Co
With no other semaglutide-related patents listed in Canadas Patent Register, the path is now clear for generic and biosimilar competitors to enter the Canadian market as early as January 2026, when regulatory data exclusivity also expires
Get Started Today Get Started Begin Your Regeneration Schedule a consultation with our medical team to learn if GHK-Cu copper peptide therapy is right for your skin health, tissue repair, and regenerative goals
7301 West Palmetto Road, Suite 103A Boca Raton, FL 33433 820 Lafayette St Cape Coral, FL 33904 5561 N University Drive, Suite 104 Coral Springs, FL 33067 13450 Parker Commons Blvd, Suite 105 Fort Myers, FL 33912 719 Rodel Cove, Suite 1031 Lake Mary, FL 32746 8095 Spyglass Hill Road, Unit 105 Melbourne, FL 32940 5495 Bryson Drive, Suite 413 Naples, FL 34109 899 Outer Road, Suite A Orlando, FL 32814 100 Madrid Blvd, Suite 313 Punta Gorda, FL 33950 3202 Henderson Blvd, Suite 104 Tampa, FL 33609 Why wait for your consultation with our weight loss doctors and nutrition coaches
Important Notes Practical considerations for consistency and safety